DRUG
GLP-1 receptor agonist
2mg once weekly via subcutaneous injection
Status
Recruiting
Phase
Phase 2
Enrollment
110
Locations
2
Results
Not posted
Publications
0
Study summary
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. At the cellular and animal experimentation levels, GLP-1R agonist demonstrated reversal of some pathogenic processes in cSVD. However, its application to cSVD patients remains to be elucidated. Investigator aims to investigate the safety and efficacy of GLP-1R agonist in patients with moderate-to-severe cSVD.
In this single-center, open-label (assessor blinded), randomized controlled study, 110 patients with cSVD of Age-Related White Matter Changes Scale of 2 or 3 will be randomized into "treatment arm" with GLP-1R agonist and standard medical therapy, and "control" arm with standard medical therapy alone in a 1:1 ratio. In this 78 weeks pilot study, investigators shall evaluate the tolerability and safety profile of GLP-1R agonist in SVD patients, together with changes in clinical, imaging and sonographic parameters. Clinical and biochemical measures will be assessed at baseline, 12 weeks, 26 weeks and 52 weeks. Transcranial Doppler Ultrasound (TCD) will be performed at baseline, 12 weeks, 26 weeks, 52 weeks and 78 weeks. MRI will be performed at baseline and 78 weeks
Interventions
DRUG
2mg once weekly via subcutaneous injection
Timeline
First posted
May 2, 2022
Study start
May 25, 2022
Primary completion
May 2027
Study completion
Dec 2027
Results posted
Not reported
Registry updated
Jun 5, 2026
Outcomes
Change of Brain Peak Width of Skeletonized Mean Diffusivity
Time frame · Baseline and week 78
Peak Width of Skeletonized Mean Diffusivity is a robust, fully-automated and easy-to-implement marker for cerebral small vessel disease based on diffusion tensor imaging, white matter tract skeletonization and histogram analysis. It is a biomarker for brain MRI images.
Number of recurrent stroke
Time frame · Baseline and week 78
Record of any recurrent stroke from medical note/system
Change of Hong Kong MOntreal Cognitive Assessment
Time frame · Baseline, week 12, week 26, week 52 and week 78
Hong Kong MOntreal Cognitive Assessment (HK-MoCA) is a cognitive assessment tool. Score from 0 to 30 . The lower score reflect the worse the outcome.
Change The Chinese Geriatric Depression Scale 30
Time frame · Baseline, week 12, week 26, week 52 and week 78
The Chinese Geriatric Depression Scale is used to detect depressive mood. Score 0 to 30. The higher the score, the worse the outcome
Change of Pittsburgh sleep quality index
Time frame · Baseline, week 12, week 26, week 52 and week 78
Pittsburgh sleep quality index Chinese Version is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The questionnaire contains frequency questions related to sleep quality, each question scale from 0 to 3. The higher the score, the worse the outcome. There is no total score available for this assessment
Change of Hong Kong List Learning Test
Time frame · Baseline, week 12, week 26, week 52 and week 78
Hong Kong List Learning Test s a newly developed Chinese memory test designed for the assessment of the processes and organizational strategies involved in learning verbal information. The more negative the standard deviation the worse the outcome
Change of Neuropsychiatric Inventory
Time frame · Baseline, week 12, week 26, week 52 and week 78
Neuropsychiatric Inventory is a brief interview with a family member or friend who knows the study subject . It is used to measure behavioral symptoms. It evaluates 12 behavioral areas commonly affected in patients with dementia. It evaluates the frequency (scale from 1 to 4), severity (scale from 1 to 3), distress to caretaker (scale from 1 to 5) of each behavioral symptom. The higher the score of any area means the worse outcome. There is no total score available for this assessment
Change of disability assessment for dementia
Time frame · Baseline, week 12, week 26, week 52 and week 78
Disability assessment for dementia evaluates 11 basic daily activities of elderly people with dementia. It evaluates each activity in 3 stages: initiation, planning and organization, effective performance. Score 1 or 0 for each question. The higher the total score, the better the outcome. The total score is from 0 to 47.
Change of Gait
Time frame · Baseline, week 12, week 26, week 52 and week 78
Gait velocity will be assessed using the 8-meter walking time. Time for walking 8-m will be measured by a stopwatch. The faster of two trials will be used in the analysis The faster of the walking time the better outcome.
Change of balance
Time frame · Baseline, week 12, week 26, week 52 and week 78
Single leg stance time will be measured by asking individuals, with their hands on their hips, to balance as long as possible on one leg with an upper limit of 30 seconds. Two trials for each leg will be performed. The best time of the four trials will be used for analysis. The longer to time duration the better outcome.
Change of Pulsatility Index
Time frame · Baseline, week 12, week 26, week 52 and week 78
Pulsatility Index of Transcranial doppler ultrasound is a painless test that uses sound waves to detect medical problems that affect blood flow in your brain. It is a measure of vascular resistance of cerebral vessels. The higher the index means higher resistance and stiffness of blood vessels which lead to worse outcome. There is no minimum or maximum values available for this index.
Eligibility
Inclusion Criteria: 1. Chinese ethnicity; 2. Age 55 to 80 years old; 3. Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI; 4. Modified Functional Ambulation Classification 5 or above; 5. Montreal Cognitive Assessment (MoCA) score \< 25; 6. Both diabetic and non-diabetic patient are eligible; 7. Patient who understands the purpose and requirements of the study, and able to provide an informed consent; Exclusion Criteria: 1. Dementia or MoCA score lower than 2nd percentile of the age and education adjusted cutoff ; 2. Cerebral white matter changes unrelated to neurodegenerative, e.g. CADASIL, X-linked adrenoleukodystrophy, metabolic diseases, multiple sclerosis, etc.; 3. Contraindication to GLP-1R agonist, including thyroid carcinoma, pancreatic pathology, proliferative retinopathy, hypersensitivity to GLP-1R agonist and history of family history of multiple endocrine neoplasia; 4. BMI \<18.5kg/m2; 5. Contraindication to proposed imaging, e.g. chronic kidney disease (KDNIGO) stage 4 or above, acute kidney injury, hypersensitivity to gadolinium-based contrast, non-MRI conditional implants or prosthesis; 6. Medical condition that would not allow the patient to adhere to the protocol or complete the study.; 7. Patient with established neurodegenerative disorders (e.g. Parkinson's Disease, Alzheimer's Disease, etc.); 8. Pregnancy.
Study locations
China · Hong Kong. Showing up to 24 locations stored in the fast local snapshot.
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Chinese University of Hong Kong
Hong Kong, Hong Kong
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Johns Hopkins University · Multiple Sclerosis
Phase 2
Recruiting
120
2026-07
AstraZeneca · Pancreatic Cancer
Not applicable
Recruiting
24,000
2026-06
University Hospital, Bordeaux · Craniopharyngiomas · Hypothalamic Obesity
Phase 3
Completed
42
2026-05
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Assistance Publique Hopitaux De Marseille · Obesity · Diabetes
Phase 3
Completed
44
2026-05
University College, London · Parkinson's Disease
Phase 3
Completed
194
2026-05
Maisa N. Feghali, MD · Gestational Diabetes
Phase 4
Recruiting
13
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.